Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Niraparib
PARP Inhibitor · Antineoplastic
PARP InhibitorAntineoplastic
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Niraparib is an inhibitor of PARP enzymes, including PARP1, PARP2, and PARP3, which are involved in DNA repair. PARP inhibition results in disruption of cellular homoeostasis and cell death. These agents display enhanced antitumor activity in tumors that are BRCA-deficient.
Indications
Ovarian cancer (initiated by a specialist)Fallopian tube cancer (initiated by a specialist)Peritoneal cancer (initiated by a specialist)Treatment of deleterious germline BRCA-deficient-mutated advanced ovarian cancer following treatment with previous lines of cytotoxic chemotherapyMaintenance therapy of recurrent epithelial ovarian cancer in complete or partial response to platinum-based chemotherapyBRCA-mutated or homologous recombination–deficient, advanced ovarian cancer after first-line platinum-based chemotherapy (maintenance treatment)
Dosing
- Adult
- 300 mg orally once daily. Consider initial dose of 200 mg in patients with body-weight less than 58 kg. For dose adjustments due to side-effects, consult product literature.
Pharmacokinetics
Half-life
36 h (elimination)
Metabolism
carboxylesterases (inactivated)
Contraindications
- Uncontrolled pre-existing hypertension
Side effects
Common
AnaemiaAnxietyAppetite decreasedArthralgiaAstheniaBack painConjunctivitisConstipationCoughDepressionDiarrhoeaDizzinessDry mouthDyspnoeaEpistaxisGastrointestinal discomfortHeadacheHypertensionHypokalaemiaIncreased risk of infectionInsomniaLeucopeniaMucositisMyalgiaNauseaNeutropeniaPalpitationsPeripheral oedemaPhotosensitivity reactionRashStomatitisTachycardiaTaste alteredThrombocytopeniaVomitingWeight decreasedanemialeukopeniadyspneadiarrhea
Serious
- Pancytopenia
- Acute myeloid leukaemia (discontinue permanently)
- Myelodysplastic syndrome (discontinue permanently)
- MDS
- AML
- posterior reversible encephalopathy syndrome
- hypertension
- cardiovascular effects
Pregnancy & lactation
Pregnancy
D
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Deferiprone
Severe
Database
Clinical effect not specified
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about Niraparib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team